Annexon Stock

Annexon R&D per Employee

The R&D Spending per Employee of Annexon (ANNX) as of Aug 14, 2026 is 10.86 M USD. In the previous year, R&D Spending per Employee was 7.03 M USD — a change of 54.63% (higher).

R&D per Employee

10.86 MUSD

YoY

54.63%

Last updated:

R&D Spending per Employee of Annexon is 2026 10.86 M USD. R&D Spending per Employee of Annexon was 2025 7.03 M USD. It decreases by 54.63% higher compared to the previous year.
Access this data via the Eulerpool API

Annexon Stock analysis

What does Annexon do? Annexon Inc is a biopharmaceutical company based in South San Francisco, California. It was founded in 2011 by Doug Love, Ted Love, and Arnon Rosenthal, who had previously worked at major pharmaceutical companies such as Genentech and Novartis. The company's main goal is to develop new treatment options for neurodegenerative diseases, focusing on the development of drugs that target the autophagy process in cells to reduce damage to nerve cells and alleviate symptoms. Annexon Inc has two divisions, Annexon Biosciences and Annexon Clinical, with partnerships with renowned pharmaceutical companies to advance drug development. Its main product is ANX005, a therapeutic antibody protein that targets the role of the complement system in neurodegenerative diseases. Annexon Inc has received multiple awards for its work and innovations and has a dedicated team of scientists and executives committed to improving the lives of people with neurodegenerative diseases. Annexon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Annexon stock

R&D Spending per Employee of Annexon is 10.86 M USD in 2026.

R&D Spending per Employee of Annexon changed from 7.03 M USD to 10.86 M USD, representing a 54.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Annexon since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Annexon historically and in real time.

Access this data via the Eulerpool API

Workforce — Annexon

All Key Metrics — Annexon